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FoxO transcription factors mediate longevity 
downstream of the insulin pathway in worms and flies 
[1-5]. In mammals, the role of FoxO factors in 
longevity has not been investigated yet, but mice with 
mutations in the insulin or IGF-1 receptors are long-
lived [6, 7]. In addition, recent genetic studies on long-
lived humans have shown that single nucleotide 
polymorphisms (SNPs) in the FoxO3 gene, one of the 
four human FoxO family members, are closely linked to 
extreme longevity and the reduction in age-related 
diseases  [8-12]. These  studies  are  consistent  with  the  
 
 







































notion that mammalian FoxO3 may also be involved in 
regulating longevity. Importantly, FoxO transcription 
factors also act as tumor suppressors in mammals [13]. 
Indeed, mice in which the FoxO1, FoxO3, and FoxO4 
genes are conditionally deleted in the adults develop 
thymic lymphomas and hemangiomas [14]. In humans, 
inactivation of FoxO3 correlates with poor prognosis in 
estrogen-dependent  breast cancer [15, 16], illustrating 
the conserved role of the FoxO family in tumor 
suppression.  
 
In mammalian cells, FoxO factors act as potent 
transcriptional activators that upregulate  the expression  









































previously  known  to  be  deacetylated  by  Sirt1.  Methylation  of  FoxO3  by  Set9  decreases  FoxO3  protein  stability,  while
moderately increasing FoxO3 transcriptional activity. The modulation of FoxO3 stability and activity by methylation may be
critical  for  fine‐tuning  cellular  responses  to  stress  stimuli,  which  may  in  turn  affect  FoxO3’s  ability  to  promote  tumor
suppression and longevity. 
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cycle arrest, differentiation, apoptosis, autophagy, and 
metabolism [17-30]. Recent evidence indicates that 
FoxO factors, and in particular FoxO3, is important for 
the maintenance of adult neural and hematopoietic stem 
cells [31-35]. However, much remains unknown about 
how FoxO transcription factors integrate extracellular 
stimuli to regulate different programs of gene 
expression and cellular responses that ultimately lead to 
lifespan extension and tumor suppression. 
 
FoxO transcription factors are regulated by a wide array 
of external stimuli, ranging from insulin and growth 
factors to oxidative and nutrient stresses [36], as well as 
a variety of chemical activators such as LY294002 [37] 
and hypomethylating agents such as azacitidine and 
decitabine [38]. The principal mode of regulation of 
FoxO factors is via post-translational modifications 
(PTMs). Phosphorylation by the insulin-activated 
protein kinases Akt and SGK at three conserved sites on 
FoxO factors leads to the sequestration of FoxO in the 
cytoplasm, thereby preventing FoxO factors from 
transactivating their target genes [18, 39-42]. 
Phosphorylation of FoxO factors in response to insulin 
pathway stimulation and to cytokines also promotes the 
degradation of FoxO factors by the ubiquitin-
proteasome pathway [15, 43-46].  
 
FoxO factors are post-translationally modified at a 
number of lysine residues by ubiquitination and 
acetylation. For example, FoxO1 is polyubiquitinated 
by the SCFskp2 complex [46], and FoxO3 is 
polyubiquitinated by MDM2 and Skp-2 [47, 48], prior 
to degradation. FoxO factors can also be mono-
ubiquitinated, which promotes FoxO nuclear 
translocation and regulates FoxO transcriptional activity 
[49, 50]. Acetylation/deacetylation of FoxO factors at a 
number of lysine residues also regulates FoxO 
subcellular localization, DNA binding capacity and 
transcriptional activity towards specific target genes 
[51-61]. The large number and diversity of PTMs on 
FoxO factors have lead us to hypothesize that these 
PTMs form a ‘FoxO code’ that could regulate several 
aspects of FoxO activity [62].  
 
Methylation of lysine residues is a critical PTM for the 
regulation of histone proteins in chromatin [63]. There 
are about 50 lysine methyltransferases in mammals [64, 
65]. The Su(var), Enhancer of zeste, and Trithorax [28] 
-domain containing lysine methyltransferases are 
conserved throughout species and catalyze a variety of 
histone methylations that are critical in regulating 
chromatin structure. Interestingly, some lysine 
methyltransferases can also methylate non-histone 
proteins. For example, Set9 (also known as Set7/9 and 
KMT7) was first identified as a mono-methyltransferase 
for lysine 4 in Histone H3 (H3K4) [66], but Set9 also 
methylates several non-histone proteins, including 
transcription factors (RelA (p65), p53, ERa), enzymes 
(DNMT1, PCAF), and transcription-initiation proteins 
(TAF10) [67-73]. Set9 methylation has been shown to 
affect the protein stability of Rel, p53, ERa and 
DNMT1 [67-69, 73, 74], and to alter the recruitment of 
transcription factors and transcriptional machinery such 
as RelA and TAF10 to different promoters [71, 72]. 
These observations suggest that Set9 has a complex role 
beyond chromatin regulation.  
 
The importance of Set9 in the organism is underscored 
by the observation that half of the Set9 knockout mice 
die prior to birth [75]. Mouse embryonic fibroblasts 
(MEFs) from Set9 heterozygous and null mice are more 
susceptible to transformation than wildtype MEFs, 
suggesting that Set9, like FoxO3, acts as a tumor 
suppressor [75]. This observation, coupled with the role 
of Set9 in a variety of cellular processes also regulated 
by FoxO3, including cell cycle arrest [69, 75] and 
apoptosis [69], and the activation of Set9 by stress 
stimuli [69, 74], raised the possibility of a connection 
between Set9 and FoxO3. 
 
Here we find that the lysine methyltransferase Set9 
methylates FoxO3 directly in vitro and in cells. We 
identify a single lysine residue methylated by Set9 on 
FoxO3. This residue is important in modulating the 
transcriptional activity of FoxO3 and its stability. In 
addition to uncovering a novel non-histone substrate for 
Set9, our study identifies lysine methylation as an 
additional post-translational modification of FoxO3 that 
is likely part of the ‘code’ that modulates FoxO3’s 
activity in response to environmental stimuli. Our 
findings further our understanding of the regulation of a 
critical transcription factor involved in longevity and 





FoxO3 is Methylated by Set9 in Vitro 
 
Among the four FoxO family members, FoxO3 is the 
isoform that has been associated with human longevity 
[8-11], breast cancer suppression in humans [15, 16], 
and in the maintenance of adult hematopoietic and 
neural stem cells [31, 34], a potentially important 
process in maintaining health late in life. Thus, we 
focused on FoxO3, and screened for lysine 
methyltransferases that could methylate the N-terminal 
or C-terminal portions of FoxO3 in an in vitro 
methylation assay (Fig. 1A, B). We found that among 
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domain-containing lysine methyltransferase family, 
methylated the N-terminal domain of FoxO3 (Fig. 1A). 
We confirmed that full-length FoxO3 was methylated 
by Set9, and that only the N-terminal portion (1-300) of 
FoxO3 was methylated by Set9 (Fig. 1A-C). These 
results indicate that FoxO3 is a substrate of Set9 in vitro 
and that the site of methylation is located between 
amino acids 1-300 of FoxO3. 
 
FoxO3 is Methylated by Set9 at Lysine 271 in Vitro 
 
To identify the site(s) of methylation of FoxO3 by Set9, 
we analyzed the peptides generated by enzymatic digest 
of full-length FoxO3 that had been methylated by Set9 
in vitro using tandem mass spectrometry (Fig. 2A).   







































lysines of FoxO3 were methylated in vitro by Set9: 
K46, K149, K230, K262, K269, K270, K271, K290, 
K419. With the exception of K419, all the sites of 
methylation identified by mass spectrometry were 
located between amino acids 1-300 of FoxO3, 
consistent with our observation that this portion of 
FoxO3 was the one methylated by Set9 (see Fig. 1). 
Based on the number of peptides identified, mono-
methylation of K271 was the most prominent post-
translational modification of FoxO3 by Set9 (Fig. 2A, 
peptides in bold). K290 was also found on multiple 
peptides to be mono- or di-methylated. However, 
because Set9 has been reported to be capable of only 
mono-methylating its substrates due to the structure of 
the active site [76], it is possible that the di-methylation 
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FoxO3 methylated by Set9, we used a deletion 
approach. We found that the regions between amino 
acids 257-474 and 253-275 were heavily methylated by 
Set9, whereas the region between 215-258 only 
displayed trace levels of methylation by Set9 (Fig. 2B). 
There are five lysine residues in the portion of FoxO3 
comprised between amino acids 257-275, four of which 
that have also been identified by tandem mass 
spectrometry as methylated by Set9 (K262, K269, 
K270, K271). In contrast, the regions between amino 
acids 144-215, and 276-299 were not methylated at all 
by Set9 (Fig. 2B), suggesting that K149 and K290 are 
not major methylation sites in FoxO3, even though 
there were identified by mass spectrometry.  
 
To identify the main residue of FoxO3 methylated by 
Set9, we generated point mutants of FoxO3 for which 
K269, K270, or K271 were replaced by an arginine, 
either individually or concomitantly. We compared the 
in vitro methylation by Set9 of wildtype (WT) FoxO3 
with that of each FoxO3 mutant. The FoxO3 mutant in 
which lysine 271 was replaced by an arginine (K271R) 
was the only mutant that showed a significant decrease 
in methylation by Set9 (Fig. 2C). In addition, the double 
mutants that contained K271R (K269R/K271R and 
K270R/K271R) were no longer methylated by Set9, 
whereas the double K269R/K270R mutant showed 
levels of methylation by Set9 that were similar to that of 
WT FoxO3 (Fig. 2C). K262R and K290R mutants did 
not display lower levels of methylation as compared to 
wild type FoxO3 (data not shown). Taken together, 
these results indicate that lysine 271, a residue located 
in the second half of the bipartite nuclear localization 
sequence (NLS) of FoxO3 [77], is the primary 
methylation site on FoxO3 by Set9 in vitro (Fig. 2D).  
 
To determine if the amino acids surrounding K271 
formed a potential consensus sequence for Set9 
methylation, we aligned a 13 amino acid region 
surrounding this site in FoxO3 with regions of similar 
length surrounding the Set9-methylated lysine residues 
in previously identified substrates (Fig. 2E). This 
alignment did not reveal a clear consensus sequence for 
Set9 methylated sites, but it suggested that Set9 requires 
positively charged residues (K or R) in the vicinity of 
the methylated lysine (Fig. 2E). 
 
FoxO3 is the FoxO Family Member Most Strongly 
Methylated by Set9 
 
We next asked if Set9 also methylated other mammalian 
FoxO family members (human FoxO1, human FoxO4, 
and mouse FoxO6), as well as FoxO orthologs in other 
species (DAF-16, the worm FoxO). While we do see 
methylation of other mammalian FoxO family members 
(most noteably a fragment of mouse FoxO6) as well as 
worm ortholog DAF-16, surprisingly, FoxO3 was the 
only protein in the FoxO family that was robustly 









































To determine if there was a particularity in FoxO3 
sequence underlying the specificity of Set9 towards 
FoxO3, we aligned the region surrounding FoxO3 K271 
with that of other mammalian and non-mammalian 
FoxO family members. This analysis revealed that the 
lysine residues corresponding to K271 are conserved in 
all mammalian FoxO family members (Fig. 3B), 
suggesting that there are other parameters, such as 
secondary structure, that may influence the relative 
specificity of Set9 for FoxO3.   
Figure  3.  Set9  preferentially  methylates  FoxO3  among
FoxO family members. (A) In vitro methylation of different


























































FoxO3 is Methylated by Set9 at K271 in Human Cells 
 
To investigate whether FoxO3 is methylated by Set9 in 
mammalian cells, we generated an antibody specifically 



















































(K271me1). As an epitope, we used a branched peptide  
that contains two mono-methylated epitopes per 
molecule (Fig. 4A). To test the specificity of this 
antibody to methylated FoxO3, we performed an in 
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Set9 or a methyltransferase-deficient version of Set9 
(H297A) as the enzyme [66]. The K271me1 antibody 
recognized only WT FoxO3 that was incubated with 
WT Set9, and did not recognize FoxO3 K271R mutant 
(Fig. 4B). The K271me1 antibody did not recognize 
FoxO3 in the presence of the methyltransferase-
deficient mutant of Set9, confirming the specificity of 
this antibody (Fig. 4B). There was a minor signal from a 
degradation fragment of FoxO3 in the presence of the 
Set9 methyltransferase-deficient mutant, which might 
be due to the fact that this mutant is not completely 
deficient for methyltransferase activity in vitro. 
Together, these results indicate that the antibody is 
specific for methylation of K271 on FoxO3 in vitro. 
 
To test whether FoxO3 was methylated by Set9 in 
mammalian cells, we co-transfected human 293T cells 
with constructs encoding Flag-tagged versions of 
FoxO3 and Set9, and examined FoxO3 methylation by 
western-blot with the K271me1 antibody. We found 
that the expression of Flag-Set9 led to an increased 
methylation of WT FoxO3 (Fig. 4C). In contrast, when 
the methyltransferase-deficient Set9 mutant (H297A) 
was co-expressed with FoxO3, FoxO3 was no longer 
recognized by the K271me1 antibody (Fig. 4C). 
Furthermore, a mutant of FoxO3 containing a point 
mutation for the methylation site identified in vitro 
(K271R) was not recognized by the antibody to 
K271me1, even when co-expressed with WT Set9 (Fig. 
4C). Taken together, these results confirm that the 
antibody to K271me1 we generated is specific, and 
indicate that overexpressed Set9 can methylate FoxO3 
at lysine 271 in mammalian cells. 
 
To examine if endogenous Set9 is necessary for FoxO3 
methylation in 293T cells, we generated a stable cell 
line in which an shRNA against Set9 was introduced by 
viral transduction. The efficiency of Set9 knock-down 
in this cell line was confirmed by western-blot with an 
antibody to endogenous Set9 (Fig. 4D). To assess the 
methylation level of FoxO3 in the Set9 knock-down 
stable cell line, we immunoprecipitated Flag-FoxO3 in 
this cell line or in control cells and performed western-
blot with the K271me1 antibody. We found that this 
antibody recognized a band at the molecular weight of 
FoxO3 in cells overexpressing FoxO3 alone in the 
control cell line and that this signal was reduced in the 
stable cell line with a Set9 shRNA knock-down (Fig. 
4D). These results indicate that endogenous Set9 is 
necessary for the methylation of overexpressed Flag-
FoxO3.  
 
Conversely, to determine if endogenous FoxO3 is 
methylated by Set9 in mammalian cells, we 
overexpressed WT Set9 or the methyltransferase-
deficient mutant of Set9 (H297A) in 293T cells and 
immunoprecipitated endogenous FoxO3 from these 
cells with an antibody to FoxO3 (Fig. 4E). We then 
assessed if endogenous FoxO3 was methylated using 
the K271me1 antibody in western-blot experiments. 
This antibody detected a band at the appropriate 
molecular weight for FoxO3 when FoxO3 was 
immunoprecipitated from cells expressing WT Set9, but 
not from cells expressing the inactive H297A mutant of 
Set9 (Fig. 4E). These data indicate that endogenous 
FoxO3 is methylated by overexpressed Set9.  
 
Finally, to test if endogenous FoxO3 is methylated in 
cells by endogenous Set9, we used the stable cell line 
with Set9 knock-down. Protein lysates from these cells 
and control cells were subjected to immunoprecipitation 
with the K271me1 FoxO3 antibody and analyzed by 
western-blot using the antibody to total FoxO3 (Fig. 4F). 
These experiments revealed a band that corresponds to 
FoxO3 in the control cell line and the intensity of this 
band was reduced in the cell line with knocked down 
Set9 (Fig. 4F), indicating that endogenous FoxO3 is 
methylated by endogenous Set9 in cells.  
 
Taken together, these experiments indicate that FoxO3 
is methylated by Set9 in the human 293T cell line, and 
that Set9 is necessary and sufficient for lysine 271 
mono-methylation on FoxO3. 
 
The Methylated Form of FoxO3 Has Similar 
Localization to Total FoxO3 
 
To examine the localization of methylated FoxO3 in 
cells, we conducted immunofluorescence experiments 
on NIH 3T3 cells expressing FoxO3-GFP using the 
K271me1 antibody. When Set9 was co-transfected with 
FoxO3-GFP, the K271me1 antibody detected a signal in 
FoxO3-GFP expressing cells (Fig. 5A). The signal from 
the K271me1 was significantly reduced when either the 
methyltransferase-deficient mutant of Set9 (H297A) 
was expressed or when cells expressed the K271R 
mutant of FoxO3, indicating that the immuno-
fluorescence signal was specific for Set9 methylation of 
K271 (Fig. 5A). The localization of the methylated form 
of FoxO3 overlapped with that of total FoxO3, 
suggesting that methylation does not influence FoxO3 
subcellular localization.  
 
To further test whether methylation by Set9 affects 
FoxO3 localization, we transfected a human glioblastoma 
cell line (U87) with FoxO3-GFP and either Set9 WT or 
the methyltransferase-deficient mutant of Set9 (H297A). 
We chose the U87 cell line because these cells have high 
transfection efficiency and a relatively flat morphology, 
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FoxO3-GFP localization was scored ‘nuclear’ if the 
nucleus was clearly identifiable in the GFP channel, 
‘cytoplasmic’ if the exclusion from the nucleus was 
visible in the GFP channel, and ‘ubiquitous’ if neither of 
these conditions was met. As expected, a constitutively 

















































increased the cyto-plasmic localization of FoxO3-GFP 
(Fig. 5B). In contrast, WT Set9 expression did not 
significantly affect the localization of FoxO3-GFP, as 
compared to expression of the methyltransferase-
defective H297A Set9 mutant or the empty vector (Fig. 
5B). Thus, methylation by Set9 does not appear to 







































































































The Methylated Form of FoxO3 Associates with 
Chromatin Upon FoxO3 Activation 
 
We next sought to determine if methyl-FoxO3 is 
associated with the chromatin. We co-expressed Flag-
FoxO3 with Flag-Set9 in 293T cells under basal 
conditions or under conditions that are known to 
activate FoxO3 (serum starvation in the presence of the 
PI3K inhibitor LY294002 [18]), and we performed 
cellular fractionation experiments to separate the non-
soluble chromatin fraction (Ch) from the soluble, non-












































we observed that total FoxO3 is primarily present in the 
non-chromatin fraction (S2), with very little FoxO3 in 
the chromatin fraction (Fig. 5C). Western-blotting with 
the K271me1 antibody revealed that the distribution of 
the methylated form of FoxO3 was similar to that of 
total FoxO3, with most of the signal present in the S2 
fraction. Upon conditions that activate FoxO3, we 
found that total FoxO3 relocalized to the chromatin 
fraction (Fig. 5C). The methylated form of FoxO3 also 
relocalized to the chromatin fraction. Nuclease 
treatment of the chromatin fraction resulted in a shift in 
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FoxO3, were bound to the chromatin and not to 
membrane proteins or other cell components in the 
chromatin pellet. These results indicate that FoxO3 
relocalizes to the chromatin fraction upon activation and 
that the methylated form of FoxO3 is also found at the 
chromatin. 
 
Methylation of FoxO3 Does Not Cause Increased 
Association with Methyl-Lysine Binding Proteins 
 
Because methyl-FoxO3 is localized to the chromatin 
under after serum starvation and LY294002 treatment, 
we asked if binding proteins that are known to bind to 
methylated histones could interact with the methylated 
fraction of FoxO3 (Fig. 6). We used a protein array that 
contained 265 domains found in chromatin associated 
proteins [78], many of which are known methyl-lysine 
binding domains (including TUDOR domains, PhD 
domains, and chromo-domains) or acetyl-lysine binding 
domains (including bromo-domains, for a complete list 
see Fig. 6, lower panels). We probed this protein array 
with a biotinylated 21 amino acid peptide surrounding 
K271 of FoxO3 either non-methylated (unmethylated 
peptide) or mono-methylated at K271 (K271 mono-
methylated peptide). Peptide binding to the methyl-
lysine binding domains on the array was assessed by 
immunofluorescence with antibodies to the biotin 
moiety. We did not observe binding of the K271 mono-
methylated peptide for any of the domains present on 
the protein array (Fig. 6). These data suggest that mono-
methylation of FoxO3 does not induce the binding to 
any of these chromatin-binding domains, although we 
cannot exclude that in the context of the whole protein, 
methylated FoxO3 may bind to chromatin-binding 
proteins that ‘read’ histone marks.  
 
Methylation by Set9 Decreases the Stability of the 
FoxO3 protein 
 
Methylation by Set9 has been shown to affect the 
protein stability of RelA, Era, DNMT1 and p53 [67-69, 
73, 74]. To test the possibility that Set9 methylation 
affected FoxO3 protein stability, we co-transfected wild 
type FoxO3 together with either WT Set9 or the 
methyltransferase-deficient mutant of Set9 (H297A) in 
293T cells. We then treated the cells with a series of 
different proteasome inhibitors: ALLN, Proteasome 
Inhibitor 1 (PSI-1), and MG132. The levels of c-Jun, a 
protein known to be degraded via a proteasome 
dependent pathway was increased upon treatment with 
proteasome inhibitors, indicating that these inhibitors 
were indeed effective at blocking the proteasome (Fig. 
7A). We found that treatment of cells with proteasome 
inhibitors caused both total FoxO3 and methyl-FoxO3 
levels to increase. Interestingly, densitometry 
measurements of the relative amount of FoxO3 levels 
normalized to β-actin levels showed an increase in the 
methyl-FoxO3 levels compared to total levels of FoxO3 
when cells were treated with proteasome inhibitors (Fig. 
7A-B). Although the effects of MG132 on FoxO3 were 
not statistically significant, there was a trend towards 
increased relative levels of methylated FoxO3 in the 
presence of MG132 (Fig. 7B). Together, these results 
suggest that the methylated form of FoxO3 is less stable 
than the non-methylated version of FoxO3.   
 
FoxO3 K271R Mutant is More Stable than Wild 
Type FoxO3 
 
To further explore whether methylation at lysine 271 
might control the stability of FoxO3, we transfected 
293T cells with WT FoxO3 or the K271R mutant form 
of FoxO3 together with WT or H297A Set9, and treated 
cells with cycloheximide to block de novo translation. 
Interestingly, we found that FoxO3 K271R was more 
stable than WT FoxO3 (Fig. 7C-D). We also found that 
WT FoxO3 was slightly less stable when co-expressed 
with WT Set9 as compared to H297A Set9 (Fig. 7C-D). 
These results suggest that methylation of lysine 271 is 
important for regulating the stability of FoxO3 in cells.  
 
Set9 Leads to a Modest Increase in Nuclear FoxO3 
Transcriptional Activity 
 
To test if Set9 affected FoxO3 transcriptional activity, 
we co-transfected 293T cells with Set9 (WT or 
methyltransferase-deficient  mutant [H297A]), together 
with FoxO3 (WT, K271R, a constitutively nuclear 
mutant in which all three Akt phosphorylation sites 
have been converted to alanines [TM], and the 
combined mutant TM K271R), and with a luciferase 
reporter construct that contained 6 FoxO DNA binding 
elements (6xDBE) (Fig. 7E). Co-expressing Set9 WT 
together with the constitutively nuclear form of FoxO3 
(FoxO3 TM) led to a modest, but significant increase in 
the luciferase reporter activity compared to co-
expression of the methyltransferase-deficient form of 
Set9 and FoxO3 TM (Fig. 7E). This result suggests that 
Set9 increases FoxO3 transcriptional activity. The TM 
K271R mutant of FoxO3 had an increased luciferase 
activity compared to TM FoxO3, probably because 
mutating K271 increased stability of the TM mutant 
(Fig. 7E). However, Set9 did not further increase 
luciferase levels when the TM K271R mutant of FoxO3 
was coexpressed (Fig. 7E), suggesting that methylation 
at K271 is necessary for the activation of FoxO3 
mediated transcriptional activation.  
 
Taken together, these studies indicate that FoxO3 is 
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tion, but decreases FoxO3 protein stability while eliciting 




















































Extracts  were  analyzed by  western‐blot  with  antibodies  to  K271me1,  Flag,  c‐Jun,  and  b‐actin.  (B)  Western‐blots  from  (A)  were
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Lysine methylation of non-histone proteins has been 
recently found to be critical for a number of cellular 
responses, including the response to stress stimuli [68, 
69, 72, 74]. In several cases, methylation affects the 
status of other post-translational modifications (PTMs) 
present on the target protein [72]. Lysine 271, the Set9 
methylation site on FoxO3 has been previously shown 
to be acetylated [54]. Thus, methylation at FoxO3 lysine 
271 could block acetylation at this site. It is possible 
that the competition for modifying lysine 271 could 
partly control FoxO3-dependent responses to stress 
stimuli. Like other PTMs, FoxO3 K271 methylation 
might be regulated by external stimuli. Indeed, we have 
found that oxidative stress can change the level of 
FoxO3 K271 methylation under certain conditions (data 
not shown). It is possible that the activity of protein 
deacetylases, such as Sirt1, which can deacetylate K271 
(A.B., unpublished data), could facilitate methylation at 
this residue and therefore act in partnership with Set9 to 
regulate the presence of the methylated form of FoxO3 
at the chromatin and increase FoxO3 transcriptional 
activity.  
 
The conservation of lysine 271 and the residues 
surrounding this lysine in all FoxO family members, 
and yet the absence of significant methylation of 
FoxO1, FoxO4, and FoxO6 by Set9 indicates that the 
mechanism of target identification by Set9 could be 
more complex than a simple consensus sequence. 
Comparison of the known Set9 targets does not display 
a clear consensus for residues surrounding the lysine 
residue that is methylated. All of the targets have at 
least one positively charged residue N- or C-terminal to 
the site of methylation, so the active site of Set9 could 
require a local positive charge interaction for 
methylation or the positively charged residue could be 
important for hydrogen bonding with a residue in Set9. 
This was shown to be the case for p53 [69]. In addition, 
all of the substrates have a negatively charged residue at 
position +4 or +5 compared to the methylation site, and 
this negative charge could be important in positioning 
the substrate for methylation. However, given the lack 
of a strong consensus sequence, it is probable that the 
substrates of Set9 need to have a secondary structure 
that is not immediately identifiable from the amino acid 
sequence. The Set9 crystal structure with a p53 peptide 
was found to be similar to that of the Set9 crystal 
structure with a mono-methyl H3 peptide [69, 76]. The 
necessity of the lysine side chain of the residue to be 
methylated to enter a narrow channel in order to access 
the methyl-donor cofactor illustrates how important 
secondary structure of the substrate is for Set9 activity. 
It is possible that the substrate must have a flexible 
secondary structure, much like a histone tail, in order to 
allow the lysine side chain access to this channel within 
Set9. 
 
The regulation of FoxO3 activity by methylation could 
be pivotal to precisely modulate FoxO3’s activity in 
response to stress. The increase in FoxO3 activity 
combined with a decrease in stability could create a 
transient pulse of FoxO3 activity intended to upregulate 
genes to mount an immediate response to stress. An 
increase in activity and decrease in stability has also 
been seen as a consequence of deacetylation on the 
FoxO family [59], consistent with a possible 
coordinated action of deacetylation and methylation. 
Mutations that increase the transcriptional activity of 
FoxO proteins without decreasing FoxO stability often 
lead to apoptosis (as is the case with the TM mutation). 
Thus, a transient pulse of FoxO activity may 
preferentially lead to the upregulation of stress 
resistance genes, without resulting in the upregulation 
of apoptosis genes. 
 
Lysine methylation of FoxO3 represents a previously 
unidentified type of post-translational modification that 
adds to the growing number of PTMs on this 
transcription factor. Together, FoxO3 PTMs may form a 
‘code’ for fine-tuning the activity of this transcription 
factor in cells. Interestingly, there seem to be interaction 
between the different FoxO3 PTMs. For example, 
arginine methylation of FoxO1 by PRMT1 has recently 
been described to inhibit the phosphorylation, and 
subsequent degradation, of FoxO1 by Akt [79]. Much 
like lysine methylation, arginine methylation can have a 
potent impact on the transcriptional activity of non-
histone substrates [80]. It will be interesting to 
determine if lysine and arginine methylation both occur 
on the FoxO3 molecule and how they might interact 
with one another. The interaction between the different 
PTMs of FoxO3 at the same residue (e.g. 
acetylation/methylation/ubiquitination of a given lysine 
residue) or at different residues (e.g. lysine methylation 
versus arginine methylation) may alter several 
properties of the FoxO3 protein, including its stability, 
subcellular localization, recruitment to a subset of target 
genes, and interaction with protein partners.   
 
Different PTMs might also serve to modulate FoxO3 
activity differentially in different tissues and cellular 
environments.  For example, a very recent study showed 
that Set9 also methylates FoxO3 at lysine 270, and that 
K270 methylation diminishes FoxO3’s pro-apoptotic 
activity in neuronal cells by preventing FoxO3 binding 
to the promoter of the pro-apoptotic gene Bim [81].   
This is in contrast with our study, since we find that 
methylation of FoxO3 at lysine 271 induces a modest 
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by reporter assay – in 293T cells. It will be interesting 
to compare how methylation at lysine 270 and 271 
modulate FoxO3 activity, and whether their effects on 
FoxO3 function is dependent on the cell type or the type 
of target genes.  
 
Together with published data, our results indicate that 
FoxO3, a transcription factor critical for stress 
resistance and longevity in a wide range of species, has 
evolved to be a heavily post-translationally regulated 
molecule, with about thirty different post-translationally 
modified residues described so far. FoxO3 appears to be 
a ‘hub’ in a network of genes regulating cellular 
homeostasis and energy metabolism. Thus, the variety 
and complexity of FoxO3 PTMs may be critical for the 
interface between extrinsic stimuli and intrinsic 
networks that regulate plastic phenotypes, including 





Antibodies. The FoxO3 antibody (‘NFL’) was described 
previously [18]. The Flag and Set9 antibodies were 
obtained from Sigma and Cell Signaling Technologies, 
respectively. The H2B antibody was obtained from 
Millipore. The c-Jun, and β-actin and GFP (3E6 
monoclonal) antibodies were purchased from Santa 
Cruz, Novus Biologicals and Invitrogen, respectively. 
The mono-methyl-specific antibody was generated by 
Quality Controlled Biochemicals. A branched mono-
methylated peptide encompassing human FoxO3 K271 
(Fig. 4A) was synthesized by the Keck Biotechnology 
Resource Laboratory at Yale University. This peptide 
was coupled to Keyhole limpet hemocyanin and 
injected into rabbits for antibody production. The serum 
was purified on a streptavidin column bound to a biotin 
conjugated linear mono-methyl peptide synthesized by 
the Keck Biotechnology Resource Laboratory. 
 
Reagents. LY294002, ALLN and PSI-1 were all 
obtained from EMD Biosciences/Calbiochem. MG132 
and Cycloheximide were purchased from Sigma.  
 
Constructs. The constructs encoding GST-FoxO1, GST-
FoxO3, GST-FoxO4, and GST-FoxO6 in the pGex 
vector were described previously [18, 82]. The 
constructs encoding His-Set9 (WT and H297A) in the 
pET-28b vector, and Flag-Set9 (WT and H297A) in the 
pcDNA vector were described previously [66]. The 
Dot1, Suv420h1, and Set8 constructs were described 
previously [83]. The SetD4, Smyd4, Smyd1, and NSD3 
were generated as fusion proteins between GST and the 
full-length human proteins and expressed in insect cells 
(X.S. and O.G.). The reporter construct 6xDBE-
luciferase was described previously [84]. The constructs 
encoding WT FoxO3, the T32A/S253A/S315A (TM) 
mutant, and the K269R/K270R/K271R mutant in the 
pECE expression vector were described previously [18, 
54, 77]. The construct encoding the constitutively active 
form of Akt (Akt CA) was described [18]. The FoxO3-
GFP construct was described previously [15]. The 
FoxO3-GFP K271R mutant was generated using site-
directed mutagenesis (Stratagene) using the forward 
primer GCGCAGCCAAGAAGAGGGCAGCCCTGCA 
GACAGC. The mutants of FoxO3 lysine residues were 
generated in the pECE vector using site directed 











shRNA oligonucleotides directed at human Set9 were 
designed with pSico Oligomaker v1.5 
(http://web.mit.edu/jacks-lab/protocols/pSico.html).  
shRNA Set9 F: 
TGAACTTTGTTCACGGAGAATTCAAGAGATTCT
CCGTGAACAAAGTTCTTTTTTC 
shRNA Set9 R: 
TCGAGAAAAAAGAACTTTGTTCACGGAGAATC
TCTTGAATTCTCCGTGAACAAAGTTCA 
These oligonucleotides were annealed and cloned into 
pSicoR (PSR) between the HpaI and Xho1 sites 
according and annealed as described 
(http://web.mit.edu/jacks-lab/protocols/pSico.html). 
 
Protein purification. His-Set9 WT and H297A were 
purified using TALON Metal Affinity Resin according 
to the protocol provided by the manufacturer (BD 
Biosciences Clonetech).  GST fusion proteins were 
purified on Glutathione agarose beads (Sigma), 
according to the manufacturer’s protocol.  
 
Cell culture - HEK293T, U87, and NIH3T3 cells were 
maintained in Dulbecco Modified Eagle Medium 
(DMEM, Invitrogen) supplemented with 10% Fetal 
Bovine Serum (FBS, Invitrogen) and 1% 
Penicillin/Streptomycin/Glutamine (P/S/Q, Invitrogen). 
When indicated, cells were serum-starved by washing 
once with DMEM + 1% P/S/Q and then incubating 
them overnight in DMEM + 1% P/S/Q. Cells were then 
treated with the PI3K inhibitor LY294002 (EMD 
Biosciences, 20 μM) for 2 hours prior to lysing. 
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Luciferase Assays. 293T cells were seeded at the 
density of 1.25 x 105 cells per well in 24 well plates. In 
each well, 250 ng of the appropriate FoxO3 constructs 
and 50 ng of the Set9 constructs were co-transfected 
with 250 ng of the 6xDBE luciferase reporter constuct 
[84] and 50 ng of the Renilla control construct using 
TransIT-293 (Mirus, 2 μl per well). Twenty-four hours 
after transfection, cells were lysed in 100 μl of 1x 
passive lysis buffer (Promega). After centrifugation to 
remove cellular debris, the luminescence was measured 
in a Wallac Victor2 multilabel counter using the Dual-
Luciferase reporter assay system (Promega), according 
to the manufacturer’s protocol. 
 
In Vitro Methylation Assay. In vitro methylation assays 
were conducted in a total volume of 25 μl using 2 μg of 
substrate, 100 ng of Set9 WT or H297A, in the 
methylation buffer: 150 mM NaCl, 20mM Tris-HCl [pH 
7.5], 1 mM EDTA, 0.02% Triton. Depending on the 
reaction, either 40 µM S-Adenosyl methionine (SAM, 
Sigma) or 300 nM S-[methyl-3H] Adenosyl-L-
Methionine (Perkin Elmer, 0.55 µCi per reaction) was 
added. Reactions were carried out at 37°C for 3 hours to 
overnight. The reaction was resolved by SDS-PAGE 
(10%). After electrophoresis the gel was incubated with 
EN3HANCE™ Autoradiography Enhancer (Perkin 
Elmer cat#6NE9701) as directed by the supplier. The 
gel was then dried and autoradiographed at -80°C in a 
BioMax TranScreen LE Intensifying Screen along with 
Kodak “Biomax” MS film. 
 
Generation of Stable Cell Lines. 293T cells were seeded 
at 3.5 x 106 cells per 10 cm plate and transfected with 
10 μg of the shRNA PSR constructs together with 5 μg 
of the VSVg and 5 μg of the Δ8.2 helper plasmids [85] 
using a calcium phosphate procedure. The medium was 
changed 12 hours after transfection. 293T cells (2.5 x 
106 cells/ml in 10 cm plates) were infected by 0.45 μm-
filtered supernatent from virus-producing cells in the 
presence of 8 µg/ml polybrene. The cells were infected 
3 times every 24 hours. After the third infection, the 
cells were seeded at a density of 2.5 x 106 cells per 10 
cm plate and treated with 7 μg/ml of puromycin. After 3 
days, the puromycin resistant cells were maintained 
with 5 μg/ml puromycin. 
 
Western-Blot Analysis. Protein lysates for western-blot 
were prepared in two different ways. Cells from a 10 
cm plate were lysed in 500 μl of Triton lysis buffer (50 
mM Tris-HCl [pH 7.5], 100 mM NaCl, 0.5 mM EDTA, 
0.4% Triton, 50 mM NaF, 40 mM β-glycerophosphate, 
1 mM sodium orthovanadate, 1 mM PMSF, 0.055 
units/ml aprotinin). Cell extracts were collected and 
centrifuged at 16,000 g for 10 min. Supernatant was 
collected and boiled in Laemmli sample buffer (2% 
SDS, 10% glycerol, 5% b-mercaptoethanol, 63 mM 
Tris-HCl [pH 6.8], 0.0025% bromophenol blue) at 95°C 
for 1 min. Alternatively, to ensure chomatin and 
membrane bound proteins were collected, cells were 
lysed in RIPA buffer (50 mM Tris-HCl [pH 7.5], 150 
mM NaCl, 20 mM EDTA, 1% NP-40, 0.1% SDS, 1 
mM PMSF, EDTA-free protease inhibitor cocktail 
[Roche]). Collected extracts were sonicated for 45 s on 
a VirTris Virsonic Digital 600 at 6W, and then 
centrifuged at 16,000 g for 10 min.  The supernatent 
was incubated at 70°C for 10 min in Laemmli sample 
buffer. Extracts were resolved on a by SDS PAGE 
(10%) and transferred to nitrocellulose membranes. The 
membranes were incubated with primary antibodies 
(K271me1, 1:500; FoxO3 NFL, 1:500; Flag, 1:2000; b-
actin, 1:5000; Set9, 1:2000; H2B, 1:5000), and the 
primary antibodies were visualized using horseradish 
peroxidase-conjugated secondary antibody 
(Calbiochem) and ECL Western-Blot Detection 
Reagent (Amersham Biosciences). 
 
Cell Fractionation. Small-scale fractionation was carried 
out as described previously [86]. Briefly, the 
cytoplasmic fraction was collected by incubating 
scraped cells in Buffer A (10 mM HEPES [pH 7.9], 10 
mM KCl, 1.5 mM MgCl2, 0.34 M Sucrose, 10 % 
Glycerol, 1 mM DTT, 0.1% Triton-X-100, EDTA-free 
protease inhibitor cocktail [Roche]) for 10 min, and 
nuclei were separated by centrifugation at 1,300 g for 5 
m in.  T he  n uc le i w e r e  t he n  ly s e d in  B uf f e r  B  ( 3 m M 
EDTA, 0.2 mM EGTA, 1 mM DTT, EDTA-free 
protease inhibitor cocktail [Roche]) for 30 min on ice. 
Chromatin and other insoluble cell parts were separated 
from nucleoplasm fraction by centrifugation at 1,700 g 
for 5 min. All fractions were incubated at 70°C for 10 
min in Laemmli sample buffer. The chromatin fraction 
was sonicated in Laemmli sample buffer for 30 s at 6W. 
Different fractions were analyzed by western-blot as 
described above.  
 
Scoring of FoxO3 Subcellular Localization in U87 Cells 
U87 cells were plated in 12 well plates on glass 
coverslips at a density of 3 x 105 cells per well. The 
cells were transfected using TransIT-293 (Mirus, 4 μl 
per well) according to the supplier’s protocol. For each 
transfection, 0.8 µg of FoxO3-GFP plasmid and 0.4 µg 
of Set9 plasmid was used. Cells were fixed 2 days post 
transfection with 4% paraformaldehyde (PFA) for 15 
minutes. They were then washed 5 times with 1x PBS. 
Coverslips were mounted using Vectashield Hard Set 
with Dapi (Vector Laboratories) and examined under a 
Zeiss Axioskop2 Plus with a FLuoArc Ultraviolet 
module. Counting of FoxO3-GFP subcellular 
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minimum of 200 cells were counted per condition for 
each experiment. If the outline of the nucleus was 
clearly visible in the GFP channel, FoxO3 localization 
was scored as cytoplasmic. If the nucleus was clearly 
visible in the GFP channel, FoxO3 localization was 
scored as nuclear. If neither of these conditions were 
met, FoxO3 localization was scored as ubiquitous. 
Statistics were done on the percentage of cells in each 
condition over 3 independent experiments and 
significance was determined using a Bonferroni posttest. 
 
Immunofluorescence in NIH3T3 cells. NIH3T3 cells 
were plated in 6 well plates on poly-L-lysine coated 
glass coverslips at a density of 106 cells/well. Cells 
were transfected with FoxO3-GFP or FoxO3-GFP 
K271R and Flag-Set9 WT or H297A at a ratio of 
4µg:6µg Foxo:Set9 using Lipofectamine 2000 
(Invitrogen, 10 μl per well), according to the 
manufacturer’s protocol.  Cells were fixed 24 hours 
post-transfection with 4% PFA for 15 min. Cells were 
then washed 5 times with 1x PBS. Coverslips were 
blocked with PBS supplemented with 3% BSA and 
0.1% Triton X-100 (PBS-BT) and stained with DAPI, 
mouse anti-GFP 3E6 monoclonal antibody  (Invitrogen, 
1:500), K271me1 polyclonal antibody (1:500) and 
appropriate secondary antibodies labeled with Alexa 
Fluor 488 (anti-mouse IgG) or 594 (anti-rabbit IgG), 
respectively (Invitrogen, 1:250). Coverslips were 
mounted using anti-fade mounting medium containing 
PBS, glycerol and P-phenylenediamine. Coverslips 
were imaged on an Axiovert 200M (Zeiss) equipped 
with a CCD camera (Hamamatsu c47429512ERG). 
Coverslips were imaged in a blinded manner. Contrast 
enhancement was performed using Photoshop CS3 
(Adobe). 
 
Tandem Mass Spectrometry Analysis. A Coomassie-
stained band corresponding to GST-FoxO3 methylated 
by Set9 was excised from an SDS-polyacrylamide gel, 
divided in half, reduced with dithiothreitol, alkylated 
with iodoacetamide, and digested with either trypsin or 
chymotrypsin. Peptide mixtures were separated by 
microcapillary reverse-phase chromatography and 
analyzed online in a hybrid linear ion trap-Orbitrap 
(LTQ-Orbitrap; Thermo Electron) mass spectrometer 
[87]. Mass spectra were data base-searched using the 
SEQUEST algorithm. All peptide matches were initially 
filtered based on enzyme specificity, mass measurement 
error, XCorr and DCorr scores and further manually 
validated for peptide identification and site localization. 
 
Generation of Protein Microarray, Peptide Synthesis, 
and Labeling. The generation of protein microarrays has 
been described [78]. Methylated and unmethylated 
forms of the K271 biotinylated peptide were 
synthesized by the W. M. Keck Biotechnology 
Resource Center (New Haven, CT). Biotinylated 
peptides (10 μg) were labeled as previously described 
[78]. A GenePix 4200A scanner (Axon, Inc.) was used 
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